Literature DB >> 22325939

Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation.

Ayman W El-Hattab1, Jean W Hsu, Lisa T Emrick, Lee-Jun C Wong, William J Craigen, Farook Jahoor, Fernando Scaglia.   

Abstract

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is one of the most common mitochondrial disorders. Although the pathogenesis of stroke-like episodes remains unclear, it has been suggested that mitochondrial proliferation may result in endothelial dysfunction and decreased nitric oxide (NO) availability leading to cerebral ischemic events. This study aimed to assess NO production in subjects with MELAS syndrome and the effect of the NO precursors arginine and citrulline. Using stable isotope infusion techniques, we assessed arginine, citrulline, and NO metabolism in control subjects and subjects with MELAS syndrome before and after arginine or citrulline supplementation. The results showed that subjects with MELAS had lower NO synthesis rate associated with reduced citrulline flux, de novo arginine synthesis rate, and plasma arginine and citrulline concentrations, and higher plasma asymmetric dimethylarginine (ADMA) concentration and arginine clearance. We conclude that the observed impaired NO production is due to multiple factors including elevated ADMA, higher arginine clearance, and, most importantly, decreased de novo arginine synthesis secondary to decreased citrulline availability. Arginine and, to a greater extent, citrulline supplementation increased the de novo arginine synthesis rate, the plasma concentrations and flux of arginine and citrulline, and NO production. De novo arginine synthesis increased markedly with citrulline supplementation, explaining the superior efficacy of citrulline in increasing NO production. The improvement in NO production with arginine or citrulline supplementation supports their use in MELAS and suggests that citrulline may have a better therapeutic effect than arginine. These findings can have a broader relevance for other disorders marked by perturbations in NO metabolism. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22325939      PMCID: PMC4093801          DOI: 10.1016/j.ymgme.2012.01.016

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  32 in total

Review 1.  Diseases of the mitochondrial DNA.

Authors:  D C Wallace
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

2.  Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation.

Authors:  Y Goto; S Horai; T Matsuoka; Y Koga; K Nihei; M Kobayashi; I Nonaka
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

Review 3.  The L-arginine-nitric oxide pathway.

Authors:  S Moncada; A Higgs
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

4.  Increased protein nitration in mitochondrial diseases: evidence for vessel wall involvement.

Authors:  Gaetano Vattemi; Yehia Mechref; Matteo Marini; Paola Tonin; Pietro Minuz; Laura Grigoli; Valeria Guglielmi; Iveta Klouckova; Cristiano Chiamulera; Alessandra Meneguzzi; Marzia Di Chio; Vincenzo Tedesco; Laura Lovato; Maurizio Degan; Guido Arcaro; Alessandro Lechi; Milos V Novotny; Giuliano Tomelleri
Journal:  Mol Cell Proteomics       Date:  2010-12-14       Impact factor: 5.911

5.  Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs.

Authors:  D Tsikas; R H Böger; S M Bode-Böger; F M Gutzki; J C Frölich
Journal:  J Chromatogr B Biomed Appl       Date:  1994-11-18

6.  Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets.

Authors:  L Castillo; T E Chapman; M Sanchez; Y M Yu; J F Burke; A M Ajami; J Vogt; V R Young
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

Review 7.  Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts.

Authors:  M Hirano; S G Pavlakis
Journal:  J Child Neurol       Date:  1994-01       Impact factor: 1.987

8.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.

Authors:  P Vallance; A Leone; A Calver; J Collier; S Moncada
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

Review 9.  Cellular ADMA: regulation and action.

Authors:  Tom Teerlink; Zaiming Luo; Fredrik Palm; Christopher S Wilcox
Journal:  Pharmacol Res       Date:  2009-08-12       Impact factor: 7.658

10.  L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation.

Authors:  R M Palmer; D D Rees; D S Ashton; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1988-06-30       Impact factor: 3.575

View more
  50 in total

1.  Arginine and citrulline for the treatment of MELAS syndrome.

Authors:  Ayman W El-Hattab; Mohammed Almannai; Fernando Scaglia
Journal:  J Inborn Errors Metab Screen       Date:  2017-03-24

2.  Late onset MELAS with m.3243A > G mutation and its association with aneurysm formation.

Authors:  Kun Zhu; Shuang Li; Huan Chen; Yao Wang; Miao Yu; Hongyan Wang; Weijie Zhao; Yunpeng Cao
Journal:  Metab Brain Dis       Date:  2017-03-21       Impact factor: 3.584

3.  Arginine metabolic endotypes in pulmonary arterial hypertension.

Authors:  Christina C Kao; Samuel H Wedes; Jean W Hsu; Kurt M Bohren; Suzy A A Comhair; Farook Jahoor; Serpil C Erzurum
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 4.  Mitochondrial biogenesis: regulation by endogenous gases during inflammation and organ stress.

Authors:  Hagir B Suliman; Claude A Piantadosi
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 5.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 6.  Therapies for mitochondrial diseases and current clinical trials.

Authors:  Ayman W El-Hattab; Ana Maria Zarante; Mohammed Almannai; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2017-09-18       Impact factor: 4.797

Review 7.  Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases.

Authors:  Kei Murayama; Masaru Shimura; Zhimei Liu; Yasushi Okazaki; Akira Ohtake
Journal:  J Hum Genet       Date:  2018-11-21       Impact factor: 3.172

8.  Nuclear recruitment of neuronal nitric-oxide synthase by α-syntrophin is crucial for the induction of mitochondrial biogenesis.

Authors:  Katia Aquilano; Sara Baldelli; Maria R Ciriolo
Journal:  J Biol Chem       Date:  2013-11-14       Impact factor: 5.157

9.  Glucose metabolism derangements in adults with the MELAS m.3243A>G mutation.

Authors:  Ayman W El-Hattab; Lisa T Emrick; Jean W Hsu; Sirisak Chanprasert; Farook Jahoor; Fernando Scaglia; William J Craigen
Journal:  Mitochondrion       Date:  2014-07-30       Impact factor: 4.160

10.  Extrarenal citrulline disposal in mice with impaired renal function.

Authors:  Juan C Marini; Inka C Didelija; Marta L Fiorotto
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.